4,123 Shares in Arcellx, Inc. (NASDAQ:ACLX) Acquired by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. bought a new position in shares of Arcellx, Inc. (NASDAQ:ACLX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,123 shares of the company’s stock, valued at approximately $316,000.

Other large investors have also bought and sold shares of the company. Bank of New York Mellon Corp grew its stake in shares of Arcellx by 23.4% during the 4th quarter. Bank of New York Mellon Corp now owns 144,409 shares of the company’s stock worth $11,075,000 after acquiring an additional 27,350 shares in the last quarter. HealthInvest Partners AB grew its stake in shares of Arcellx by 4.6% during the 4th quarter. HealthInvest Partners AB now owns 42,071 shares of the company’s stock worth $3,296,000 after acquiring an additional 1,841 shares in the last quarter. Y Intercept Hong Kong Ltd grew its stake in shares of Arcellx by 98.1% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 7,735 shares of the company’s stock worth $593,000 after acquiring an additional 3,831 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of Arcellx by 7.5% during the 4th quarter. New York State Common Retirement Fund now owns 20,243 shares of the company’s stock worth $1,552,000 after acquiring an additional 1,415 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D bought a new position in shares of Arcellx during the 4th quarter worth approximately $1,838,000. 96.03% of the stock is owned by institutional investors.

Insider Transactions at Arcellx

In other news, insider Rami Elghandour sold 38,300 shares of Arcellx stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $62.02, for a total transaction of $2,375,366.00. Following the completion of the sale, the insider now owns 149,186 shares of the company’s stock, valued at approximately $9,252,515.72. This trade represents a 20.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher Heery sold 10,155 shares of Arcellx stock in a transaction on Monday, February 24th. The stock was sold at an average price of $63.79, for a total value of $647,787.45. Following the sale, the insider now directly owns 37,486 shares of the company’s stock, valued at $2,391,231.94. This represents a 21.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,370 shares of company stock valued at $4,189,641. 6.24% of the stock is currently owned by corporate insiders.

Arcellx Price Performance

Shares of Arcellx stock opened at $68.88 on Thursday. The business has a fifty day simple moving average of $68.00 and a two-hundred day simple moving average of $77.59. Arcellx, Inc. has a 1 year low of $47.88 and a 1 year high of $107.37. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of -97.01 and a beta of 0.29.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The business had revenue of $15.27 million for the quarter, compared to analyst estimates of $27.42 million. As a group, equities analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ACLX shares. Morgan Stanley raised their price target on shares of Arcellx from $81.00 to $106.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 6th. Bank of America increased their price objective on Arcellx from $84.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Arcellx in a report on Tuesday, December 10th. Barclays raised Arcellx to a “strong-buy” rating in a report on Friday, November 29th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $105.00 price objective on shares of Arcellx in a report on Monday, December 9th. Thirteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $108.46.

Arcellx Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).